药物涂层球囊在冠状动脉大血管原发病变中应用的研究进展

张峰; 陈欣

doi:10.13201/j.issn.1001-1439.2020.10.017

药物涂层球囊在冠状动脉大血管原发病变中应用的研究进展

张峰,
陈欣^,

- 天津市第一中心医院心脏科(天津, 300192)

详细信息

通讯作者: 陈欣,E-mail:chenxin966@126.com

中图分类号: R541.4

收稿日期: 2020-04-06

修回日期: 2020-05-19

Research progress of drug-coated balloon application in large de novo coronary artery lesions

ZHANG Feng,
CHEN Xin^,

- Department of Cardiology, Tianjin First Center Hospital, Tianjin, 300192, China

More Information

Corresponding author: CHEN Xin, E-mail: chenxin966@126.com

Received Date: 06 April 2020

Revised Date: 19 May 2020

摘要

摘要: 药物涂层球囊(DCB)是球囊扩张术和药物涂层技术结合的产物。DCB既能将抑制再狭窄的药物输送释放至治疗段血管,又没有金属植入物,使“介入无植入”成为可能。已有多项临床研究验证了DCB在支架内再狭窄(ISR)治疗中的优越性。冠状动脉原发病变是指除支架内、桥血管病变的冠状动脉自身血管病变。对于冠状动脉大血管(一般定义为直径≥2.8 mm)的原发病变,植入药物洗脱支架(DES)仍是主要治疗手段。目前有多项研究对DCB在冠状动脉大血管原发病变中的应用做了尝试和评价,本文就此作一综述。
- 药物涂层球囊 /
- 冠状动脉大血管 /
- 原发病变
Abstract: Drug-coated balloon(DCB) is a combination of balloon dilatation and drug-coating technology. DCB not only can deliver the drug to the treated vessel, but also has no metal implant, which makes "leave nothing behind" possible. Several clinical studies have demonstrated the superiority of DCB in the treatment of in-stent restenosis. De novo coronary artery lesions refer to native coronary artery lesions except in-stent restenosis and bypass graft lesions. A large coronary artery is commonly defined as a vessel with a diameter≥2.8 mm. While drug-eluting stent implantation is still the primary therapeutic method for large de novo coronary artery lesions, many trials have tried and evaluated the application of DCB in large de novo coronary artery lesions. This article reviews this issue.
- drug-coated balloon /
- large coronary artery /
- de novo lesions

HTML全文

参考文献(29)

[1]	Cortese B,di Palma G,Latini RA,et al.Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions.The FAtebenefratelli SIrolimus COated-balloon(FASICO)registry[J].Cardiovasc Revasc Med,2017,18(7):487-491.
[2]	《药物涂层球囊临床应用中国专家共识》专家组.药物涂层球囊临床应用中国专家共识[J].中国介入心脏病学杂志,2016,24(2):61-67.
[3]	Kolh P,Windecker S,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:the Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS).Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].Eur J Cardiothorac Surg,2014,46(4):517-592.
[4]	Unverdorben M,Vallbracht C,Cremers B,et al.Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis:the three-year results of the PEPCAD II ISR study[J].EuroIntervention,2015,11(8):926-934.
[5]	Xu B,Gao R,Wang J,et al.A prospective,multicenter,randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis:results from the PEPCAD China ISR trial[J].JACC Cardiovasc Interv,2014,7(2):204-211.
[6]	Jeger RV,Farah A,Ohlow MA,et al.Drug-coated balloons for small coronary artery disease(BASKET-SMALL 2):an open-label randomised non-inferiority trial[J].Lancet,2018,392(10150):849-856.
[7]	Megaly M,Rofael M,Saad M,et al.Outcomes with drug-coated balloons in small-vessel coronary artery disease[J].Catheter Cardiovasc Interv,2019,93(5):E277-E286.
[8]	Yang JQ,Peng JH,Xu T,et al.Meta-analysis of the effects of drug-coated balloons among patients with small-vessel coronary artery disease[J].Medicine(Baltimore),2019,98(22):e15797.
[9]	Li M,Guo C,Lv YH,et al.Drug-coated balloon versus drug-eluting stent in de novo small coronary vessel disease:A systematic review and meta-analysis[J].Medicine(Baltimore),2019,98(21):e15622.
[10]	Sim HW,Ananthakrishna R,Chan SP,et al.Treatment of very small de novo coronary artery disease with 2.0 mm drug-coated balloons showed 1-year clinical outcome comparable with 2.0 mm drug-eluting stents[J].J Invasive Cardiol,2018,30(7):256-261.
[11]	Mathey DG,Wendig I,Boxberger M,et al.Treatment of bifurcation lesions with a drug-eluting balloon:the PEPCAD V(Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease)trial[J].EuroIntervention,2011,7 Suppl K:K61-65.
[12]	López Mínguez JR,Nogales Asensio JM,Doncel Vecino LJ,et al.A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions(BABILON trial):24-month clinical and angiographic results[J].EuroIntervention,2014,10(1):50-57.
[13]	Kleber FX,Rittger H,Ludwig J,et al.Drug eluting balloons as stand alone procedure for coronary bifurcational lesions:results of the randomized multicenter PEPCAD-BIF trial[J].Clin Res Cardiol,2016,105(7):613-621.
[14]	Megaly M,Rofael M,Saad M,et al.Outcomes With Drug-Coated Balloons for Treating the Side Branch of Coronary Bifurcation Lesions[J].J Invasive Cardiol,2018,30(11):393-399.
[15]	Patel S,Svermova T,Burke-Gaffney A,et al.Drug-eluting balloons with provisional bail-out or adjunctive stenting in de novo coronary artery lesions-a systematic review and meta-analysis[J].Cardiovasc Diagn T-her,2018,8(2):121-136.
[16]	Rissanen TT,Uskela S,Eränen J,et al.Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk(DEBUT):a single-blind,randomised,non-inferiority trial[J].Lancet,2019,394(10194):230-239.
[17]	Shin ES,Ann SH,Balbir Singh G,et al.Fractional flow reserve-guided paclitaxel-coated balloon treatment for de novo coronary lesions[J].Catheter Cardiovasc Interv,2016,88(2):193-200.
[18]	Uskela S,Kärkkäinen JM,Eränen J,et al.Percutaneous coronary intervention with drug-coated balloononly strategy in stable coronary artery disease and in acute coronary syndromes:An all-comers registry study[J].Catheter Cardiovasc Interv,2019,93(5):893-900.
[19]	Lu W,Zhu Y,Han Z,et al.Short-term outcomes from drug-coated balloon for coronary de novo lesions in large vessels[J].J Cardiol,2019,73(2):151-155.
[20]	邱竞,韩战营,王玺,等.药物包被球囊治疗冠状动脉大血管原位病变的疗效观察[J].中华心血管病杂志,2019,47(6):452-456.
[21]	Yu X,Ji F,Xu F,et al.Treatment of large de novo coronary lesions with paclitaxel-coated balloon only:results from a Chinese institute[J].Clin Res Cardiol,2019,108(3):234-243.
[22]	于雪,季福绥,许锋,等.紫杉醇涂层球囊治疗直径2.8mm及以上冠状动脉原发病变的效果[J].中华心血管病杂志,2018,46(1):32-38.
[23]	Liu Y,Zhang YJ,Deng LX,et al.12-Month clinical results of drug-coated balloons for de novo coronary lesion in vessels exceeding 3.0mm[J].Int J Cardiovasc Imaging,2019,35(4):579-586.
[24]	李成洋,陈宏.冠状动脉内超声指导下紫杉醇药物涂层球囊用于治疗冠状动脉狭窄26例近期临床疗效[J].临床心血管病杂志,2018,34(1):27-29.
[25]	危小良,王晓进,赵婷,等.紫杉醇药物涂层球囊治疗冠状动脉原发大血管病变的疗效和安全性研究[J].中国动脉硬化杂志,2019,27(2):150-155.
[28]	Köln PJ,Scheller B,Liew HB,et al.Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting-A feasibility and safety study[J].Int J Cardiol,2016,225:262-267.
[29]	Onishi T,Onishi Y,Kobayashi I,et al.Drug-coated balloon angioplasty for de novo small vessel disease including chronic total occlusion and bifurcation in real-world clinical practice[J].Cardiovasc Interv Ther,2019,34(2):139-148.
[30]	Ho HH,Tan J,Ooi YW,et al.Preliminary experience with drug-coated balloon angioplasty in primary percutaneous coronary intervention[J].World J Cardiol,2015,7(6):311-314.
[31]	GobićD,Tomulić V,LulićD,et al.Drug-coated balloon versus drug-eluting stent in primary percutaneous coronary intervention:A feasibility study[J].Am JMed Sci,2017,354(6):553-560.